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Accounting for ancestral diversity is essential in medical genomics. For this reason, inclusion 
of Indigenous and other under-represented populations in genomic research is necessary to 
ensure equitable outcomes and access to precision medicine and disease prevention. Here 
we discuss this issue in the context of a national program of pre-conception expanded 
carrier screening (ECS) for recessive monogenic diseases, funded by the Australian 
Government as part of its Genomics Health Futures Mission. Current knowledge and 
research about monogenic diseases are mainly based on people with European ancestry and 
little is known about pathogenic DNA variants in people of Aboriginal and/or Torres Strait 
Islander descent. We argue that significant effort is required to build the evidence base and 
genomic reference data required before ECS can bring significant clinical benefit for many 
Aboriginal and/or Torres Strait Islander Australians. Research programs and creation of 
reference data are required to correct this bias. They are essential steps to achieving the 
Australian Government’s objectives and its commitment “to leveraging the benefits of 
genomics in the health system for all Australians”. They require culturally safe, community-
led research and community engagement embedded within national health and medical 
genomics programs that ensure that new knowledge is integrated into medicine and health 
services in ways that address the cultural and health needs of Indigenous people. Until this 
occurs, Australians of European ancestry stand to benefit most and, as a consequence, 
Indigenous Australians and other minority groups in the Australian population are at risk of 
being, in relative terms, further disadvantaged.
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Introduction 2 
Monogenic diseases account for most rare diseases (diseases with a prevalence of less than 3 
5 in 10,000), 70% of which occur exclusively in children1. These diseases can have 4 
devastating consequences for affected people and their families. Individually – since most 5 
are rare – they contribute little to the overall burden of disease. Collectively, however, they 6 
have a substantial effect on the disease burden in all countries, regardless of socio-economic 7 
conditions affecting health2,3. It is estimated that there are more than 10,000 separate 8 
monogenic diseases4 affecting ~6% of the human population1,5. 9 
Genomic technologies have enabled major advances in understanding and treating rare 10 
monogenic diseases. Greater accessibility to genomic data and the knowledge to interpret it 11 
have: improved diagnostic rates for existing conditions; greatly expanded the number of 12 
diseases for which diagnostic tests are available; led to greater understanding of biological 13 
processes underlying pathology; enabled development of better and targeted therapies; and 14 
resulted in improved prenatal and preimplantation testing6–10. Genomic technologies have 15 
also created the possibility of pre-conception expanded carrier screening (ECS), by which 16 
prospective parents are simultaneously screened as potential carriers of many different 17 
recessive diseases5,11–14.  18 
Pre-reproductive carrier screening is generally targeted at specific genes and carried out 19 
where there is increased risk of a child being born with a specific condition due to ancestry 20 
or based on clinical information15. It has been extremely effective, e.g., in reducing the 21 
incidence of Tay-Sachs disease (MIM: 272800) in Ashkenazi Jewish populations around the 22 
world16,17. ECS is an extension of this approach that involves simultaneous screening for 23 
many pathogenic variants responsible for a broad range of diseases in the general 24 
population. This broad-scale approach to screening is achieved by sequencing the entire 25 
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genomes (genome sequencing) or the fraction of the genome that encodes proteins – the 26 
exome (exome sequencing) – of prospective parents. Although data are obtained for the 27 
whole genome or exome, screening is often targeted at a predetermined subset of genes 28 
and/or variants. 18,19,25 29 
The Australian government is evaluating the potential benefits and challenges that ECS 30 
presents5,20–28 with a view to its introduction into the national healthcare system29. Our 31 
focus here is on the significant challenges of achieving inclusion and equitable benefits for 32 
Indigenous Australians from this procedure and, by extension, medical genomics generally. 33 
While our focus is on Indigenous Australians, many of the points we raise apply to other 34 
under-represented groups in the general population. 35 
Ethical, cultural, social and policy considerations are of over-riding importance in genomics. 36 
Implementation of ECS in Aboriginal and Torres Strait Islander communities raises questions 37 
about: the cultural appropriateness of screening in different communities; how prospective 38 
parents should be counselled and appropriately informed about the procedure; the means 39 
by which consent should be obtained; the potential impact on social and cultural norms; the 40 
potential for group, family and/or individual stigmatisation; how screening can be integrated 41 
into cultural practices, lifestyles and traditional concepts; whether the autonomy of patients, 42 
families and communities can be preserved; the proportion of the population likely to 43 
benefit from the procedure; how screening will be administered through community 44 
controlled and other local health services; and whether there is the capacity for counselling 45 
and follow-up clinical care. Fully articulating these complex issues is a substantial 46 
undertaking that would need separate, detailed treatment to do it full justice. Consequently, 47 
we address only the salient points here. Our main focus is on scientific evidence about 48 
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genetics and its medical implications for Indigenous Australians, as a foundation to better 49 
inform such a discussion. 50 
The core problem for ECS implementation is lack of knowledge about genomic variants in 51 
Indigenous populations and of appropriate clinical and genomic reference data. Carrier 52 
screening depends on prior knowledge of pathogenic variants, most of which comes from 53 
studies of people of European ancestry, which may have limited applicability to other 54 
populations30–43.  55 
Australia is a culturally and ancestrally diverse nation. There is a need, therefore, to 56 
recognise how genomic information is interpreted, incorporated and translated meaningfully 57 
in the lives, experiences, and healthcare of individuals from diverse cultural and ethnic 58 
backgrounds. In particular, there is a national imperative to ensure equitable benefit for 59 
Aboriginal and Torres Strait Islander Australians, who collectively experience significant 60 
disparity in morbidity and mortality44 and access to health services44,45 compared with non-61 
Indigenous Australians.  62 
We discuss how Indigenous involvement at all levels, from co-design to governance and 63 
implementation, within national health genomics initiatives such as ECS is required to ensure 64 
that the needs of Aboriginal and Torres Strait Islander people are met, and to avoid the risk 65 
of their further marginalization, disadvantage and disillusion. Such involvement is essential 66 
for these initiatives to deliver outcomes consistent with the equity principles that underpin 67 
Australia’s public healthcare system: universal cover and universal access. 68 
Medical genomics in Australia 69 
The national introduction of ECS is being evaluated as part of the Genomics Health Futures 70 
Mission (GHFM), a program funded by the Medical Research Future Fund (MRFF). Projects 71 
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funded through the GHFM operate within the policy settings provided by Australia’s National 72 
Health Genomics Policy Framework (NHGPF) developed by the Australian Health Ministers’ 73 
Advisory Council (AHMAC) and agreed by the Council of Australian Governments (COAG) 74 
Health Ministers in November 2017 (Box 1).  75 
The NHGPF recognizes the importance of addressing the requirements for Indigenous 76 
inclusion in the implementation of genomic medicine (Box 1). We focus specifically on ECS as 77 
the first application of genomics to be funded under the GHFM, as a way of highlighting the 78 
importance of proactive Indigenous leadership in the design and development of medical 79 
genomics programs in Australia.  80 
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 81 
Pathogenic variants are generally rare and population-specific 82 
Most monogenic diseases are caused by as many as thousands of different DNA variants in 83 
one or more specific genes5, almost all of which are rare. They may be found only in one 84 
geographic region, in one small community, or even in a single family. Thus, for example, 85 
Box 1. The National Health Genomics Policy Framework, 
Medical Research Future Fund (MRFF) and Genomic Health 
Futures Mission (GHRM) 
The NHGPF provides the blueprint for embedding genomics in the Australian health system. It 
“presents a shared commitment to leveraging the benefits of genomics in the health system for all 
Australians” 
The principles underpinning NHGPF priorities are: 
• The application of genomic knowledge is ethically, legally and socially responsible and 
community trust is promoted 
• Access and equity are promoted for vulnerable populations  
• The application of genomic knowledge to health care is supported and informed by 
evidence and research. 
Recognising the importance of equity and inclusion, particularly in relation to Indigenous 
Australians, the priority areas of action of the National Health Genomics Policy Framework 2018–
2021 include: 
• 1.5. exploring the potential for discrimination, and evaluating the delivery of genomic 
services in terms of being accessible, appropriate and culturally secure and responsive for 
Aboriginal and Torres Strait Islander peoples. 
• 5.2. Promote culturally safe and appropriate genomic and phenotypic data collection and 
sharing that reflects the ethnic diversity within the Australian population, including for 
Aboriginal and Torres Strait Islander peoples. 
The intended outcomes of the Medical Research Future Fund (MRFF) are:  
1. life changing discoveries such as new treatments, drugs and devices  
2. continuous improvement and innovation in the health system that benefits all Australians  
3. strengthening domestic research capacity through support, collaboration and the 
development of expert talent  
4. positioning Australia’s health and medical research sector at the forefront of the 
innovation economy  
5. improving Australia’s reputation as a global leader in health and medical research.  
The objective of the Genomics Health Futures Mission (GHFM) is to: 
1. deliver better diagnostics and targeted treatments 
2. avoid unnecessary health costs  
3. improve patient experience and outcomes. 
The fund supports research projects that aim to: 
1. provide the pathways for the development of new diagnostics, medicines and treatments 
from genomics research  
2. expand genomics research effort and reach, allowing researchers and commercial partners 
to sustain efforts in discovery 
3. build evidence for scaling applications, and build new markets  
4. ensure that later stage translation and flagship work is not hampered by a lack of 
investment in early research.  
 7 
more than 2,000 different known pathogenic variants in the CFTR gene (MIM: 602421) can 86 
cause the recessive monogenic disease cystic fibrosis (CF; MIM: 219700; http:// 87 
www.genet.sickkids.on.ca/Home.html). Approximately 1 in 3,000 people are affected by CF 88 
in northern Europe46. Elsewhere, it is much rarer and usually caused by local, rare variants 89 
that are not found in European patients47. In China, for example, CF, although rare, affects 90 
an estimated 20,000 people, nearly as many as the ~30,000 people affected in the United 91 
States. Because pathogenic CFTR variants are different from those in Europe, carrier 92 
screening panels designed for ancestrally European populations do not detect CF carriers in 93 
China or in the many substantial Chinese communities elsewhere in the world48,49.  94 
The rarity and geographically restricted origins of pathogenic variants have important 95 
consequences for Australia’s diverse society.  96 
1. The makeup of pathogenic variants is likely to be unique, reflecting the unique diversity 97 
of Indigenous peoples and the ancestral makeup of settlers and immigrants. 98 
2. For the same reasons, it is likely that there are many pathogenic variants that have not 99 
been previously characterized. These may cause different clinical phenotypes and 100 
treatment responses even if they have similar molecular properties to known variants50 101 
46. Clinical and functional investigation will generally be required to establish their 102 
pathogenicity and associated disease phenotypes11,51,52.  103 
3. For recessive diseases, many novel combinations of pathogenic variants are likely. A 104 
recessive disease can be caused by (n(n-1)/2)+n combinations of n pathogenic variants. 105 
Only a small fraction of these combinations can occur where the geographic distribution 106 
of variants is restricted. In a diverse society with many people of mixed ancestry, 107 
however, many novel combinations of variants are likely that may cause novel disease 108 
phenotypes and have novel effects on treatment. 109 
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4. Genomic-background, environment and lifestyle are more likely to influence the 110 
phenotypic manifestation of pathogenic variants, potentially causing normally 111 
pathogenic variants to become benign 53 or normally benign variants to become 112 
pathogenic54,55 because: 113 
I. The environment and lifestyle of many people has rapidly changed due to 114 
changed economic or social circumstances, changes in diet, or as a result of 115 
displacement or migration.  116 
II. There are many people of mixed ancestry in whom the effect of a variant on 117 
disease may have changed after it arrived in a genomic background different to 118 
the one in which it had previously existed. 119 
Pathogenic variants in Aboriginal and Torres Strait Islander 120 
communities 121 
Global prevalence estimates1,5 suggest that, to a first approximation, more than 30,000 122 
Aboriginal and Torres Strait Islander people may be affected by monogenic diseases, and 123 
that many more may be carriers of pathogenic variants. Many of these variants will be 124 
different from those causing the same diseases in people of non-Indigenous ancestry in the 125 
broader Australian population. Many are likely to cause either formerly unknown diseases or 126 
phenotypic manifestations of known diseases that have not previously been encountered in 127 
a clinical setting. 128 
Some Aboriginal and/or Torres Strait Islander people have pathogenic variants inherited 129 
from non-Indigenous ancestors. However, with few exceptions, like Machado-Joseph 130 
Disease 56–58 and a complex phenotype resulting from an MTOR gene variant59, little is 131 
known about pathogenic variants originating within Indigenous communities. 132 
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Unpublished data compiled by the National Centre for Indigenous Genomics (NCIG) for 160 133 
people from four Aboriginal communities show that: 134 
1. Approximately 25% of all DNA variants in the genome of an Aboriginal person, 135 
disregarding variants inherited from non-Aboriginal ancestors, are unknown in people 136 
from outside Australia. Among the large number of Aboriginal and Torres Strait Islander-137 
specific variants the will be some that are pathogenic. These will not be represented in 138 
international or Australian clinical databases or in current screening panels. These 139 
databases and panels may, therefore, be of limited value for screening in Aboriginal and 140 
Torres Strait Islander communities. 141 
2. Of these Aboriginal-specific variants, ~40% are likely to be found in a single region or 142 
community. Overall, based on FST distances60 and comparison with data from the Simons 143 
Genome Diversity Project61, genomic differences among Aboriginal communities across 144 
Australia are as great as those between populations across Europe and Asia combined. Thus, 145 
using information about people from the Northern Territory, for example, as a basis for 146 
treating people in South Western Australia, would be equivalent to treating people in the UK 147 
based on information about people from Cambodia. 148 
Current lack of evidence means that for many people of Aboriginal and/or Torres Strait 149 
Islander descent ECS will produce greater uncertainty, revealing more ‘likely-pathogenic 150 
variants’ (LPVs) and ‘variants of unknown significance’ (VUSs) than for European Australians. 151 
This uncertainty could potentially lead to inappropriate clinical intervention if benign 152 
variants are incorrectly reported as pathogenic, as has occurred elsewhere62–64.  153 
The risk of variants being falsely reported as pathogenic can be avoided by increasing the 154 
threshold of evidence required to assign pathogenicity. This approach, however, tends to 155 
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result in under-reporting of pathogenic variants because some do not meet the higher 156 
threshold of evidence. 157 
The result is greater “residual risk”, i.e. more couples who are at reproductive risk that is not 158 
identified by ECS. High residual risk is of concern even if negative findings are not reported. If 159 
prospective parents are properly informed about their increased residual risk, negative 160 
findings may cause significant levels of needless anxiety and concern (Box 2).  161 
In addition, increasing the threshold of evidence for pathogenicity reduces the “yield”, i.e. 162 
the number of couples identified as being at risk. The result is that, overall, fewer people 163 
benefit from screening65. This effect will be particularly pronounced for people of Aboriginal 164 
and/or Torres Strait Islander descent for whom a greater proportion of detected variants will 165 
be novel. If the expected yield for the general population is 1–2%, the lower expected yield 166 
for Indigenous couples means that many hundreds of couples may be screened without any 167 
of them receiving a report that they are at risk of giving birth to a child with a monogenic 168 
disease.  169 
Lack of knowledge about variant pathogenicity adds to the challenges of counselling 170 
prospective Aboriginal and Torres Strait Islander parents and of supplying the accurate 171 
information they need in order to make informed decisions about undergoing ECS. This point 172 
can be illustrated by considering information that prospective parents would require for 173 
their consent to be fully informed (See Box 2).  174 
Novel variants identified through ECS can be functionally and clinically investigated. These 175 
investigations are unlikely, however, to provide useful information to prospective parents 176 
because of the time required to carry them out. They may, nevertheless, give rise to new 177 
evidence that improves the quality of screening for future patients.  178 
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These indirect benefits might provide ethical justification for ECS as a medical intervention if 179 
it were not possible to obtain them in other ways, even if there is little potential benefit and 180 
considerable risk for patients. Novel pathogenic variants can, however, be more effectively 181 
identified and their phenotypic effects better characterized at greatly reduced risk through 182 
direct clinical investigation of affected patients and their families. This more direct approach 183 
is greatly enhanced by characterization of genomic variation in patient communities, which 184 
can be critically important for variant discovery 59,64,66 and for correct assignment of 185 
pathogenicity 62–64. 186 
How to address the current disparity? 187 
The validity of ECS depends on a preexisting evidence-base linking specific DNA variants with 188 
disease phenotypes, which has been painstakingly built up through decades of careful direct 189 
clinical investigation of affected patients and relevant family members11,51,52,67 mainly in 190 
people of European ancestry. Equitable inclusion of Indigenous Australians in the benefits of 191 
ECS, and medical genomics more generally, requires a similar level of evidence.  192 
The critical importance of ancestry in the many other areas of health care where genomics 193 
now plays an important role 30–43 has led to programs aimed at achieving diversity in 194 
genomics, e.g., India 68, Asia 69; Africa 70; Aotearoa/New Zealand 71,72, USA 73.  195 
An equitable approach in Australia would require prioritization of research involving people 196 
of Aboriginal and/or Torres Strait Islander descent, as well as other under-represented 197 
groups, as an integral part of national medical genomics programs. The approach must build 198 
on existing community engagement and leadership, and avoid duplicated effort that leads to 199 
an unnecessary burden on communities. National programs should include: 1. Detailed 200 
characterization of genomic variation in Aboriginal and Torres Strait Islander peoples; and 2. 201 
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Careful study, with community involvement and leadership, of pathogenicity and the general 202 
clinical, cultural and social consequences of diseases. 203 
Programs must be designed and sufficiently resourced to include Indigenous community 204 
leadership to ensure appropriate research conduct at a time when community acceptance of 205 
genomics is critically important74. As in other areas of healthcare57,75–79, extending 206 
approaches developed for the general population or retrofitting systems that were not 207 
designed to meet the specific needs of Indigenous people will not be effective and may do 208 
more harm than good. Hence, there is a need, at all levels and stages, for Indigenous co-209 
design and development and incorporation of Indigenous data governance and 210 
custodianship as the foundations of national medical genomics programs. 211 
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Finally, it is essential to account for the significant genomic differences as well as the 212 
significant socio-cultural differences among the many Indigenous communities across the 213 
Australian continent. 214 
Conclusion 215 
ECS is one of many medical applications of genomics that, collectively, can transform the 216 
healthcare system for the better. For these developments to contribute usefully to the 217 
Box 2. Appropriate information for prospective ECS participants 
of Aboriginal and/or Torres Strait Islander descent 
If you decide you want pre-reproductive carrier screening, we will sequence both of your genomes 
to characterise DNA variants in a panel of genes. We have chosen these genes because we know 
that if both parents have certain variants in these genes there is a chance that their child will be 
affected by a serious disease. If we discover that this is the case for you, we can inform you of the 
risk, which will allow you to make a more informed decision about your reproductive options. 
Because you are an Aboriginal/Torres Strait Islander couple, it is likely that you will have variants in 
these genes that have not been detected before in people from other parts of the world. Most of 
these variants are likely to be benign, but some of them may cause disease. However, because the 
variants that are only in Aboriginal and Torres Strait Islander people have not been researched, we 
won’t know. We refer to these kinds of variants as either likely-pathogenic variants (LPVs), if they 
are similar to pathogenic variants we do know about, or as variants of unknown significance (VUSs).  
Because at least one of you is of Aboriginal/Torres Strait Islander descent, we are less likely to find 
variants that we can be sure are either pathogenic or benign, and it is more likely that we will 
discover LPVs, than would be the case if you were a European Australian couple.  
The reason is that we have chosen genes with variants that are known to cause diseases in 
European people because they have been extensively studied over many decades. In contrast, we 
know almost nothing about pathogenic variants that people have because of their Aboriginal 
and/or Torres Strait Islander descent.  
Even if we find variants that we know are pathogenic or benign in European Australians, it is likely 
that we will not be sure that they will also be pathogenic or benign for your child, because the effect 
of a variant can depend on other parts of your genomes and on your lifestyle and environment.  
There is a reasonable chance that after the screening we will have to advise you that you share 
variants that might put you at risk of having a child with a disease but that we can’t be sure. This 
outcome is more likely for you than it would be if you were a European Australian couple. 
Some people find this uncertainty distressing because they are left feeling that they could make a 
bad decision either way. If they avoid reproducing or terminate a pregnancy it may be for no good 
reason. Alternatively, if they give birth, the child might have a serious genetic disease, which the 
doctors don’t know much about because they have never treated someone with a disease like this 
before. 
You can instruct us not to tell you about LPVs we find during the screening. If you decide to do this, 
we cannot guarantee that LPVs we find are not pathogenic. You may, therefore, decide to have a 
child despite both being carriers of variants that turn out to be pathogenic.  
We have councillors available to help you with your feelings if this should happen for you. 
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health and wellbeing of Indigenous Australians the current dearth of evidence and lack of 218 
reference data must be addressed. Communities must be empowered through Indigenous 219 
leadership, co-conceptualization and co-design of national programs to ensure culturally 220 
safe conduct, and the principles of Indigenous sovereignty over genomic data must be 221 
implemented 222 
Australia has an opportunity to embrace the challenges presented by the cultural and 223 
ancestral diversity of its people to deliver research and clinical outcomes with significant 224 
global impact. New discoveries leading to therapeutic innovation are more likely from clinical 225 
investigation of people whose health and disease have previously been neglected, and of 226 
illnesses, which, until now, have been ignored, than from focussing on better understood 227 
problems in well-studied populations. 228 
In addition, addressing the specific requirements of Indigenous Australians and other under-229 
represented groups would directly support the Australian Government’s commitment to 230 
equity and inclusion. It would redress past inequities and provide a model for better 231 
healthcare practice in Australia and internationally. 232 
Australia has a unique opportunity for medical genomics innovation leading to improved 233 
prediction, prevention, treatment and cure of disease that is based on the distinctive 234 
characteristics of genomic diversity and its relationship to disease in Indigenous people, a 235 
reflection of their continuing ancient presence on the Australian continent80,81. This 236 
comparative advantage derives from Australia’s ancient history. In realising it, the central 237 
role and importance of Aboriginal and Torres Strait Islander peoples must be recognised, 238 
they must be at the forefront of national programs, and they must stand to gain an equitable 239 
share of the resulting benefits. 240 
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